Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.

Kumar A, Vardhana S, Moskowitz AJ, Porcu P, Dogan A, Dubovsky JA, Matasar MJ, Zhang Z, Younes A, Horwitz SM.

Blood Adv. 2018 Apr 24;2(8):871-876. doi: 10.1182/bloodadvances.2017011916.

2.

Recreation economics to inform migratory species conservation: Case study of the northern pintail.

Mattsson BJ, Dubovsky JA, Thogmartin WE, Bagstad KJ, Goldstein JH, Loomis JB, Diffendorfer JE, Semmens DJ, Wiederholt R, López-Hoffman L.

J Environ Manage. 2018 Jan 15;206:971-979. doi: 10.1016/j.jenvman.2017.11.048. Epub 2017 Dec 7.

PMID:
29223107
3.

Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells.

Natarajan G, Terrazas C, Oghumu S, Varikuti S, Dubovsky JA, Byrd JC, Satoskar AR.

Oncoimmunology. 2015 Jun 9;5(1):e1057385. eCollection 2016.

4.

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F.

J Proteomics. 2016 Mar 16;136:89-98. doi: 10.1016/j.jprot.2015.12.016. Epub 2016 Jan 13.

5.

Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.

Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA.

JAMA Oncol. 2015 Aug;1(5):684-6. doi: 10.1001/jamaoncol.2015.0457. No abstract available.

PMID:
26182170
6.

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ.

Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13.

7.

Optimal population prediction of sandhill crane recruitment based on climate-mediated habitat limitations.

Gerber BD, Kendall WL, Hooten MB, Dubovsky JA, Drewien RC.

J Anim Ecol. 2015 Sep;84(5):1299-310. doi: 10.1111/1365-2656.12370. Epub 2015 May 18.

PMID:
25808951
8.

Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.

Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA.

J Biol Chem. 2015 Mar 6;290(10):5960-78. doi: 10.1074/jbc.M114.614891. Epub 2015 Jan 15.

9.

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR.

J Clin Invest. 2014 Nov;124(11):4867-76. doi: 10.1172/JCI75328. Epub 2014 Oct 1.

10.

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.

Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, Woyach JA, Byrd JC, Johnson AJ.

Blood. 2014 Dec 4;124(24):3583-6. doi: 10.1182/blood-2014-07-587279. Epub 2014 Sep 25.

11.

The B-cell receptor pathway: a critical component of healthy and malignant immune biology.

Zhong Y, Byrd JC, Dubovsky JA.

Semin Hematol. 2014 Jul;51(3):206-18. doi: 10.1053/j.seminhematol.2014.05.007. Epub 2014 May 15. Review.

PMID:
25048784
12.

Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases.

Zhong Y, Johnson AJ, Byrd JC, Dubovsky JA.

Postdoc J. 2014 Jun;2(6):1-11.

13.

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.

Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, Freeman GJ, Serody JS, Murphy WJ, Munn DH, Sarantopoulos S, Luznik L, Maillard I, Koreth J, Cutler C, Soiffer RJ, Antin JH, Ritz J, Dubovsky JA, Byrd JC, MacDonald KP, Hill GR, Blazar BR.

Blood. 2014 Jun 19;123(25):3988-98. doi: 10.1182/blood-2014-03-562231. Epub 2014 May 12.

14.

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.

Zhong Y, El-Gamal D, Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, Goettl VM, Jha S, Mo X, Jones JA, Flynn JM, Maddocks KJ, Andritsos LA, McCauley D, Shacham S, Kauffman M, Byrd JC, Lapalombella R.

Leukemia. 2014 May;28(5):1158-63. doi: 10.1038/leu.2014.9. Epub 2014 Jan 13. No abstract available.

15.

Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments.

Johnson LE, Becker JT, Dubovsky JA, Olson BM, McNeel DG.

Chin Clin Oncol. 2013 Mar 1;2(1). doi: 10.3978/j.issn.2304-3865.2012.11.06.

16.

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ.

Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.

17.

Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.

Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N.

Blood. 2013 Nov 7;122(19):3308-16. doi: 10.1182/blood-2013-05-504597. Epub 2013 Sep 5.

18.

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC.

Blood. 2013 Oct 10;122(15):2539-49. doi: 10.1182/blood-2013-06-507947. Epub 2013 Jul 25.

19.

Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine.

Dubovsky JA, Powers JJ, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz JA.

Leuk Res. 2011 Sep;35(9):1193-9. doi: 10.1016/j.leukres.2011.02.007. Epub 2011 Mar 5.

20.

A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.

Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA.

Leuk Lymphoma. 2011 Apr;52(4):668-79. doi: 10.3109/10428194.2010.550074. Epub 2011 Jan 27.

21.

Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Dubovsky JA, Wang D, Powers JJ, Berchmans E, Smith MA, Wright KL, Sotomayor EM, Pinilla-Ibarz JA.

Leuk Res. 2011 Mar;35(3):394-404. doi: 10.1016/j.leukres.2010.08.001. Epub 2010 Sep 22.

22.

Circumventing immune tolerance through epigenetic modification.

Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM.

Curr Pharm Des. 2010 Jan;16(3):268-76. Review.

PMID:
20109136
23.

Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.

Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA.

Clin Cancer Res. 2009 May 15;15(10):3406-15. doi: 10.1158/1078-0432.CCR-08-2099. Epub 2009 Apr 28.

24.

The biological basis for immunotherapy in patients with chronic myelogenous leukemia.

Pinilla-Ibarz J, Shah B, Dubovsky JA.

Cancer Control. 2009 Apr;16(2):141-52. Review.

PMID:
19337200
25.
26.

MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis.

Dubovsky JA, Albertini MR, McNeel DG.

J Immunother. 2007 Oct;30(7):675-83.

PMID:
17893560
27.

Humoral immune responses to testis antigens in sera from patients with prostate cancer.

Hoeppner LH, Dubovsky JA, Dunphy EJ, McNeel DG.

Cancer Immun. 2006 Jan 10;6:1.

Supplemental Content

Loading ...
Support Center